Christopher Gilfillan

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 586 citations

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

The high burden of inpatient diabetes mellitus: the Melbourne Public Hospitals Diabetes Inpatient Audit

Leon A. Bach, Elif I. Ekinci, Dennis Engler et al. · The Medical Journal of Australia · 2014 · 83 citations · Full text

Real-world artificial intelligence-based opportunistic screening for diabetic retinopathy in endocrinology and indigenous healthcare settings in Australia

Jane Scheetz, Dilara Koca, Myra B. McGuinness et al. · Scientific Reports · 2021 · 74 citations · Full text

Fracture prevention strategies in patients presenting to Australian hospitals with minimal‐trauma fractures: a major treatment gap

Helena Teede, I. A. Jayasuriya, Christopher Gilfillan · Internal Medicine Journal · 2007 · 58 citations

Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck

Susan Griffin, Simon Walker, Mark Sculpher et al. · Health Technology Assessment · 2009 · 52 citations · Full text